Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors

NCT02052648 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT02052648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2014
Completion date
June 20, 2019
Enrollment
160 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, glioma, gliosarcoma, malignant brain tumor